Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Gene Therapy
 More »

THIS KEYWORD IS SPONSORED BY:

  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    ... for platinum-sensitive relapsed ovarian cancer patients with BRCA gene mutations. ... plus docetaxel as a second-line therapy for patients with KRAS mutation-positive, ...
    5-16-2013
  • WATCH: The Story Behind Glybera Approval
    Late last year the European Medicines Agency (EMEA) granted marketing approval for the Western world's first gene therapy product, Glybera, which is intended for the treatment of ...
    5-16-2013
  • American Society of Gene & Cell Therapy
    Salt Lake City UT UNITED STATES http://www.asgct.org/meetings-educational-programs/asgct-annual-meetings/2013-annual-meeting
    5-15-2013
  • Inside Story Behind Glybera's Development and Approval
    Late last year the European Medicines Agency granted marketing approval for the Western world's first gene therapy product, Glybera. During this SKYPE interview, James M. Wilson, ...
    5-15-2013
  • FDA Approves Roche EGFR Mutation CDx for NSCLC
    diagnostic it has approved to detect gene mutation associated with a type of lung ... for receiving Tarceva as first-line therapy," said FDA's Alberto Gutierrez, Ph.D., ...
    5-15-2013
  • GEN Video Interview with Dr. James Wilson on the Story Behind...
    New Rochelle, NY, May 15, 2013-Late last year the European Medicines Agency (EMEA) granted marketing approval for the Western world's first gene therapy product, Glybera, which is ...
    5-15-2013
  • Induced Pluripotent Stem Cells: A U.S. Patent Landscape Analysis
    ... for in vivo therapy. Specifically, since 2009, fewer patent documents mention or recite the use of the transforming factors OCT, Myc, or Klf ("any gene" in Figure 1 ) and ...
    5-13-2013
  • Companion Diagnostics: 52 Pick-Up
    ... related to Tocagen's viral gene therapy (Toca 511 & Toca FC) for primary brain cancer, followed by potential commercialization of the diagnostic tests for therapy monitoring. ...
    5-9-2013
  • The Tumor Microenvironment as a Drug Target, Part II
    ... from various breast cancer subtypes harbored subtype-specific gene expression signatures. ... "Existing and future FAP directed therapy may be explored in conjunction with ...
    5-7-2013
  • Analytik Jena Acquires Sepsis Test Among SIRS-Lab Assets
    ... In addition to the sepsis test, SIRS-Lab was also developing a gene expression product ... Konrad Reinhart, M.D., director of the Clinic for Anesthesiology and Intensive Therapy ...
    5-6-2013
  • Turning Off Cancer's "Master Regulator"
    ... The next step, Dr. Resar says, is to try to develop a therapy based on that principle. The ... Researchers have identified a gene that, when repressed in tumor cells, puts a halt to ...
    5-3-2013
  • Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral...
    According to Edison Research Investment, Oxford BioMedica's deal with Novartis is expected to raise the gene-based therapy firm's valuation from £58.5 million ($91 million) to ...
    5-1-2013
  • Exposing the Exposome
    ... better understand environmental contributions that shape gene expression and function. ... future behavior and predict response to therapy, the integration and modeling represent, ...
    5-1-2013
  • Biomarkers Take Center Stage
    ... mutations, gene copy number aberrations, gene expression abnormalities, protein and ... Once biomarkers that may have an impact on therapy are discovered, it is not always ...
    5-1-2013
  • Twin Effort Hones In on Membrane Proteins
    ... proteins as targets for drug discovery, vaccine development, and protein therapy. ... Clients send Synthelis the gene sequence or any genetic material from a membrane protein ...
    5-1-2013
  • More »

    Journal Articles

  • Nonexpanded Mesenchymal Stem Cells for Regenerative Medicine...
    Massimo Faustini, Massimo Bucco, Theodora Chlapanidas, Giulia Lucconi, Mario Marazzi, Marta Cecilia Tosca, Paolo Gaetani, Marco Klinger, Simona Villani, Virginia Valeria Ferretti, Daniele Vigo, Maria Luisa Torre
    Tissue Engineering, Part C: Methods
    These cells are ideal candidates for use in regenerative medicine, tissue engineering, including gene therapy, and cell replacement cancer therapies. In this work, we aimed to the ...
  • Opposite Effects of Metabolic Syndrome and Calorie Restriction...
    Federico Cacciapuoti
    Metabolic Syndrome and Related Disorders
    happens through Sirtuin 1 (SIRT1), a gene/protein activated by the reduction of ... receiving conventional antiischemic therapy, in comparison with another group treated ...
  • Comparison of Viral and Nonviral Vectors for Gene Transfer to...
    Brian Kealy, Aaron Liew, Jill M. McMahon, Thomas Ritter, Aideen O'Doherty, Melissa Hoare, Udo Greiser, Erin E. Vaughan, Martin Maenz, Ciara O'Shea, Frank Barry, Timothy O'Brien
    Tissue Engineering, Part C: Methods
    Background/Aims: The ability of endothelial progenitor cells (EPCs) to home to sites of neoangiogenesis makes them attractive candidates for use in the field of gene therapy. The ...
  • Variation of Mesenchymal Cells in Polylactic Acid Scaffold in...
    Richard D. Coutts, Toshikazu Kubo, David Amiel, Yasushi Oshima, Frederick L. Harwood
    Tissue Engineering, Part C: Methods
    with time (i.e. 24 weeks). These results could be essential for achieving cartilage regeneration by cell transplantation strategies with growth factors and/or gene therapy.

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll